Lexaria Bioscience Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter) |
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code (
| |||||
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
|
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.07 Submission of Matters to a Vote of Security Holders
On January 27, 2026 at 1:00 p.m. (Pacific Time), the Company held its annual shareholder meeting (the “Meeting”). There were 8,380,389 shares of the Company represented in person or by proxy at the Meeting, constituting 37.71% of the Company’s issued share capital as at December 1, 2025, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:
Matter Being Voted On | For | Against/ Withheld | Abstain | Broker Non-Vote | Percent Approved By1 |
To Elect Richard Christopher as a director | 3,610,713 | 806,470 | - | 3,963,206 | 81.7% |
To Elect John Docherty as a director | 4,258,174 | 159,008 | - | 3,963,207 | 96.4% |
To Elect Christopher Bunka as a director | 3,779,780 | 637,402 | - | 3,963,207 | 85.6% |
To Elect Nicholas Baxter as a director | 4,082,174 | 335,009 | - | 3,963,206 | 92.4% |
To Elect William Edward (Ted) McKechnie as a director | 3,645,373 | 771,809 | - | 3,963,207 | 82.5% |
To Elect Albert Reese Jr. as a director | 3,252,873 | 1,164,310 | - | 3,963,206 | 73.6% |
To Elect Bal Bhullar as a director | 4,119,098 | 298,085 | - | 3,963,206 | 93.3% |
To Appoint Malone Bailey LLP as Auditors | 8,070,899 | 252,955 | 56,535 | - | 97.0% |
To Ratify the lawful actions of the directors for the past year | 3,913,888 | 437,312 | 65,982 | 3,963,207 | 90.0% |
1 Percentage is calculated based on abstained votes and broker non-votes not being counted as a vote against the resolution.
All of the proposals are described in detail in the Company’s proxy statement filed with the Securities and Exchange Commission on December 10, 2025.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP. | ||
| ||
/s/ Richard Christopher | ||
Richard Christopher | ||
CEO, Principal Executive Officer | ||
| ||
Date: January 28, 2026 |
3 |